FINWIRES · TerminalLIVE
FINWIRES

TD Cowen Upgrades Genmab to Buy From Hold, Raises Price Target to $43 From $32

By

Genmab (GMAB) has an average rating of Buy and mean price target of $37.62, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles

Research

Janney Downgrades Wintrust Financial to Neutral From Buy, $170 Price Target

Wintrust Financial (WTFC) has an average rating of overweight and mean price target of $176.85, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $157.24, Change: $-6.42, Percent Change: -3.93%

$WTFC
Research

Northland Securities Downgrades Calix to Outperform From Market Perform, Price Target $52

Northland Securities Downgrades Calix to Outperform From Market Perform, Price Target $52

$CALX
Research

Jefferies Downgrades UTZ Brands to Hold From Buy, $14.25 Price Target

UTZ Brands (UTZ) has an average rating of overweight and mean price target of $12.95, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $14.07, Change: $+6.62, Percent Change: +88.86%

$UTZ